2023
Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort. Journal Of Vascular And Interventional Radiology 2023, 34: 1997-2005.e3. PMID: 37468093, DOI: 10.1016/j.jvir.2023.07.010.Peer-Reviewed Original ResearchConceptsLiver transplantSurgical resectionHepatocellular carcinomaLT cohortBiliary injuryReadmission ratesAbscess formationIntensive care unit-level careLess healthcare utilizationNationally Representative CohortInitial hospital stayICU-level careAdverse event ratesEnd Results ProgramSmall hepatocellular carcinomaCare delivery outcomesFisher's exact testHealthcare Common Procedure Coding SystemChi-square testLow-intensity careLiver cancer treatmentPostprocedural hemorrhageHospital stayAdverse eventsSecondary outcomes
2017
Multicenter Trial of the VenaTech Convertible Vena Cava Filter
Hohenwalter EJ, Stone JR, O’Moore P, Smith SJ, Selby JB, Lewandowski RJ, Samuels S, Kiproff PM, Trost DW, Madoff DC, Handel J, Gandras EJ, Vlahos A, Rilling WS. Multicenter Trial of the VenaTech Convertible Vena Cava Filter. Journal Of Vascular And Interventional Radiology 2017, 28: 1353-1362. PMID: 28821379, DOI: 10.1016/j.jvir.2017.06.032.Peer-Reviewed Original ResearchConceptsVena cava filtersCava filtersDevice-related adverse eventsHigh-risk traumaAdverse event ratesSingle-arm studyFailure of anticoagulationTechnical success rateLong-term safetyConverted patientsAdverse eventsPulmonary embolismSurgical prophylaxisVenous thromboembolismMulticenter trialCaval filtersRight atriumSurgical removalClinical assessmentProcedure timePatientsEvent ratesMean timeSuccess rateMonths
2011
Complications of Portal Vein Embolization
Kodama Y, Shaw C, Madoff D. Complications of Portal Vein Embolization. 2011, 159-168. DOI: 10.1007/978-1-84882-122-4_18.Peer-Reviewed Original ResearchPortal vein embolizationVein embolizationStrict patient selectionManagement of complicationsMajor hepatectomyAdverse eventsClinical presentationPatient selectionPotential complicationsEmbolization proceduresClinical successComplicationsEmbolizationHepatectomyComplex proceduresAccess approachMorbidityEtiologyMortalityPhase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin